This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 33.33% and 9.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -7.27% and 32.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 82.35% and 8.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 10.42% and 4.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks.com featured highlights include GigaCloud Technology, SkyWest, Ramaco Resources, Eastman Chemical and Catalyst Pharmaceuticals
by Zacks Equity Research
GigaCloud Technology, SkyWest, Ramaco Resources, Eastman Chemical and Catalyst Pharmaceuticals are part of the Screen of the Week article.
Best Momentum Stocks to Buy for January 10th
by Zacks Equity Research
IMCR, CPRX and AMPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 10, 2024.
5 Value Stocks With Strong Earnings Yield to Rev Up Returns
by Rimmi Singhi
Consider investing in high-yield value stocks like GCT, SKYW, METC, EMN and CPRX to unlock your portfolio's potential.
New Strong Buy Stocks for January 10th
by Zacks Equity Research
PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.